FDA Arthritis Drug Reviewer Jeffrey Siegel Joins Genentech After Approving Company Tocilizumab
Jeffrey Siegel, an FDA staff member specializing in arthritis drug reviews, oversaw the 2010 approval of Genentech tocilizumab (Actemra) for arthritis treatment. Within months of the approval, Siegel left the FDA to join Genentech and its parent company Roche as director of the division that …
Jeffrey Siegel
FDA
Genentech
Roche
Actemra
regulatory-capture
pharmaceutical-industry
fda
revolving-door
drug-approval
Read more →